The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes

The Role of Targeted Agents and Their Effects on Lymphocytes and Patient Outcomes

NIH would be the funding source for this project.

The relationship between the immune system and cancer has been of interest to the scientific community for decades. In 1909, Erlich suggested that the immune system plays a critical role in suppressing tumor cell development, termed immunosurveillance. The lymphocyte serves an important role in this process by recognizing non-self cells and mediating cell killing through complex mechanisms. Lymphocytes that infiltrate tumors are known as tumor infiltrating lymphocytes (or TILs) and have also been linked to a more favorable predictor of survival for many tumor types including colorectal cancer, breast cancer, esophageal cancer, ovarian cancer, cervical cancer, and oral squamous cancers. On the other hand, cancer cells have developed an innate ability to escape the immune system targeting foreign cells for destruction by down regulating key players including lymphocytes. Naturally, impairment of host immunity is associated with worse outcomes.Prior studies have shown that a low lymphocyte count at diagnosis or prior to treatment is linked to a lower overall survival regardless of treatment. Fogar looked at patients with pancreas and biliary tract tumors and found that patients with cancer had lower levels of circulating lymphocytes compared to healthy controls. Patients with less than 1.2 x 109/L circulating lymphocytes had shorter survival than those with values greater than 1.2 x 109/L (p<0.01). Another study showed that pancreas cancer patients with a lower neutrophil to lymphocyte ratio (NLR) had a median overall survival of 2.4 months compared to 7.7 months in patients with a normal NLR. A lower lymphocyte count has been associated with shorter survival times in patients with various other solid tumors including colorectal, non-small cell lung cancer, and ovarian cancer. Patients with low lymphocyte counts after treatment have also been shown to have shorter survival times. Campian and colleagues looked at patients with stage III non-small cell lung cancer. Eighty-nine percent of patients had normal total lymphocyte counts (defined as > 1,000 cells/mm3) prior to receiving standard therapy. Two months after starting treatment, a 67% overall reduction of total lymphocyte counts was seen, with a median of 500 cells/mm3. This occurred irrespective of the chemotherapy regimen given. Analysis showed a 70% higher rate of death related to lower total lymphocyte counts at 2 months compared with those with a count higher than 500 cells/mm3. To date, no study has evaluated the role of targeted agents in different tumor types and their effect on lymphocyte numbers and outcomes. The purpose of our study will be to evaluate targeted agents as a single agent to determine if 1) there is a relationship with circulating lymphocytes and 2) if low lymphocyte counts related to treatment can be associated with outcome.

[{ "PostingID": 1363, "Title": "ROCHE-WO16229", "Description": "A multicenter, open-label, single-arm phase II study of safety and efficacy of a once three-weekly regimen of Herceptin monotherapy in patients with HER2-overexpressing metastatic breast cancer" },{ "PostingID": 1364, "Title": "ROCHE-TDM4374g", "Description": "A Phase II, single-arm, open-label study, of Trastuzumab-MCC-DM1 adminstered intravenously to patients with HER2-positive metastatic breast cancer" },{ "PostingID": 1365, "Title": "ROCHE-TDM4258g", "Description": "A phase II, single-arm, open-label study of Trastuzumab-MCC-DM1 administered intravenously to patients with HER2-positive metastatic breast cancer who have progressed while receiving HER2-directed therapy" },{ "PostingID": 1369, "Title": "ROCHE-NO25026 (BRIM3)", "Description": "A randomized, open-label, controlled, multicenter, global study on progression-free and overall survival in previously untreated patients with unresectable stage IIIC or stage IV melanoma with V600E BRAF mutation receiving RO5185426 or dacarbazine" },{ "PostingID": 1371, "Title": "ROCHE-SHH4476G (ERIVANCE)", "Description": "Medicine: vismodegib, Condition: other malignant neoplasms of skin, Phase: 2, Roche Clinical Study ID: SHH4476G (ERIVANCE), Sponsor: Roche ." },{ "PostingID": 14473, "Title": "ROCHE-BO20289 (Beatrice)", "Description": "An International Multi-centre Open-label 2-arm Phase III Trial of Adjuvant Bevacizumab in \"Triple Negative\" Breast Cancer." },{ "PostingID": 14474, "Title": "ROCHE-ML21217", "Description": "Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology" },{ "PostingID": 14475, "Title": "ROCHE-MEK4592G/GO01329/XL518-001", "Description": "A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of GDC-0973/XL518 Administered Orally Daily to Subjects With Solid Tumors" },{ "PostingID": 14476, "Title": "ROCHE-SHH4489G", "Description": "A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission" },{ "PostingID": 14477, "Title": "ROCHE-SHH4812G/GS01354", "Description": "A Phase II, Multicenter, Open-label, Three-cohort Trial Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC)" },{ "PostingID": 14479, "Title": "ROCHE-SHH3925G", "Description": "An Open-Label, Phase I Study of Systemic Hedgehog Pathway Antagonist, GDC-0449, in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or For Whom No Standard Therapy Exists" },{ "PostingID": 14480, "Title": "ROCHE-BO27952", "Description": "A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction" },{ "PostingID": 14481, "Title": "ROCHE-TOC2572G", "Description": "A Phase II, Open-label, Multicenter Study to Evaluate the Effect of Tumor-based HER2 Activation on the Efficacy of rhuMAb 2C4 (Pertuzumab) in Subjects With Recurrent Non-Small Cell Lung Cancer" },{ "PostingID": 14482, "Title": "ROCHE-NO25530", "Description": "An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients With Metastatic or Unresectable Papillary Thyroid Cancer (PTC) Positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine" },{ "PostingID": 14483, "Title": "ROCHE-MO25743", "Description": "An Open-label, Single-arm, Phase II, Multicenter Study, to Evaluate the Efficacy of Vemurafenib in Metastatic Melanoma Patients With Brain Metastases" },{ "PostingID": 14484, "Title": "ROCHE-ML25597", "Description": "A Single Arm, Open Label, Expanded Access Study Of RG7204 In Previously Treated Patients With Metastatic Melanoma" },{ "PostingID": 14573, "Title": "ROCHE-MO18109", "Description": "An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer" },{ "PostingID": 14574, "Title": "ROCHE-BO18279", "Description": "MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients" },{ "PostingID": 14575, "Title": "ROCHE-MO18660", "Description": "An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers" },{ "PostingID": 14576, "Title": "ROCHE-ML29453", "Description": "An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy" }]